Adoptive Immunotherapy for Head and Neck Cancer with Killer Cells Induced by Stimulation with Autologous or Allogeneic Tumour Cells and Recombinant Interleukin-2
- 1 January 1989
- journal article
- research article
- Published by Taylor & Francis in Acta Oto-Laryngologica
- Vol. 107 (5-6) , 346-351
- https://doi.org/10.3109/00016488909127519
Abstract
Peripheral blood lymphocytes drawn by leukapheresis using Haemonetics V50 were mixed and cultured with autologous or allogeneic tumour cell line to activate killer cells by tumour antigenic stimulation, and further with recombinant interleukin-2 (rIL-2). Killer cells were intra-arterially infused, as a primary therapy, in 5 patients with maxillary and one with lingual cancer (squamous cell carcinoma). Effects on reduction of primary tumour size were significantly high without any severe side effects. The effects were interpreted mainly by direct day-by-day observation of the site, findings of CT and histology. Histological findings of the tissue obtained by surgical operation performed after adoptive immunotherapy were remarkable changes, such as infiltration of lymphoid cells around the cancer nets, degeneration of cancer cells, infiltration of scavenger macrophages (giant cells) and so on. The results suggested that adoptive immunotherapy by the killer cells can be a powerful treatment to bring the cancer under control, in with combination of other therapies.Keywords
This publication has 8 references indexed in Scilit:
- Suppressor cells in the effector phase of autologous cytotoxic reactions in cancer patientsCancer Immunology, Immunotherapy, 1988
- Differences of Sensitivity to Autologous Cytotoxic Lymphocytes Between Primary Tumor and its Cervical Lymph Node MetastasesAuris Nasus Larynx, 1987
- A New Approach to the Adoptive Immunotherapy of Cancer with Tumor-Infiltrating LymphocytesScience, 1986
- In vitro sensitization and expansion with viable tumor cells and interleukin 2 in the generation of specific therapeutic effector cells.The Journal of Immunology, 1986
- Observations on the Systemic Administration of Autologous Lymphokine-Activated Killer Cells and Recombinant Interleukin-2 to Patients with Metastatic CancerNew England Journal of Medicine, 1985
- Specific cytotoxicity against autologous tumour and proliferative responses of human lymphocytes grown in interleukin 2International Journal of Cancer, 1982
- Lysis of tumor biopsy cells by autologous T lymphocytes activated in mixed cultures and propagated with T cell growth factor.The Journal of Experimental Medicine, 1982
- Regulation of the Immune Response to Tumor AntigensThe Journal of Immunology, 1976